Free Trial
→ What the hell is going on? (From Porter & Company) (Ad)tc pixel
NYSE:MANE

Veradermics Q3 2026 Earnings Results & Report

Veradermics logo
$148.60 +4.65 (+3.23%)
As of 01:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veradermics reported Q3 2026 earnings on November 10, 2026. The company reported EPS of -$0.5030.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
9:00 AM ET

Veradermics EPS Results

Actual EPS
-$0.5030
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Veradermics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Veradermics' Q3 2026 Press ReleasePress Release
(8-K)

Veradermics Q3 2026 Earnings FAQ

Veradermics (NYSE:MANE) reported earnings of -$0.5030 per share for Q3 2026. The report was announced on Tuesday, November 10, 2026.

Veradermics Earnings Headlines

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
November 10 at 8:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261110316485/en/Veradermics-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Corporate-and-Clinical-Progress/
Veradermics stock rises on 12-month hair growth trial data
November 10 at 6:58 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/veradermics-stock-rises-12-month-180414147.html
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript
November 10 at 6:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4965234-veradermics-incorporated-mane-discusses-positive-study-302-part-b-results-for-vdphl01-in
Veradermics Reports Positive Phase 2/3 Hair Loss Trial Results
November 9 at 9:31 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/veradermics-reports-positive-phase-2-3-hair-loss-trial-results?utm_source=marketbeat.com&utm_medium=referral
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
November 9 at 8:22 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/veradermics-achieved-highest-vdphl01-reported-120000900.html
See More Veradermics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veradermics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veradermics and other key companies, straight to your email.

About Veradermics

Veradermics (NYSE:MANE) is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use.

VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

View Veradermics Profile
Earnings Tools